Year :

Legend Biotech Announces FDA Clearance of IND Application for LB2102 in Extensive Stage Small Cell Lung Cancer

Somerset, N.J.—November 21, 2022—Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared Legend Biotech’s Investigational New Drug (IND) application to proceed with the clinical development of LB2102, an investigational, autologous chimeric […]

Nov 21, 2022

Legend Biotech Shares Updated Data from Comprehensive Cilta-Cel Clinical Development Program at ASH 2022

Seven accepted poster presentations showcase our continued leadership in CAR-T cell therapy research for patients with multiple myelomaNew analysis of sustained minimal residual disease (MRD) negativity from the pivotal CARTITUDE-1 study of CARVYKTI® (ciltacabtagene autoleucel, cilta-cel) in heavily pretreated adults with relapsed or refractory multiple myeloma (RRMM)First conference presentation of data from the CARTIFAN-1 study of cilta-cel in […]

Nov 03, 2022

CARVYKTI™ (ciltacabtagene autoleucel) Receives Approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

SOMERSET, N.J., – September 27, 2022 – Legend Biotech Corporation (NASDAQ: LEGN), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved CARVYKTI™ (ciltacabtagene autoleucel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy, for […]

Sep 27, 2022

Legend Biotech to Host 2022 R&D Day on Monday, October 3, 2022

SOMERSET, N.J.—September 15, 2022—Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced it will host its in-person and virtual Research & Development Day on Monday, October 3, 2022 at 10:00 a.m. ET at Andaz 5th Avenue in New York City. Please […]

Sep 15, 2022

Legend Biotech Announces Participation in Upcoming Investor Conferences

SOMERSET, N.J.— (BUSINESS WIRE)—August 19, 2022—Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced its participation in the upcoming investor conferences: Event: Citi’s 17th Annual BioPharma Conference Location: Boston, Massachusetts Fireside Chat Date & Time: Wednesday, September 7, 2022 at 11:20am […]

Aug 19, 2022

Thank you for your interest in learning more about Legend Biotech.
Send us your questions or concerns.

Media Relations & Communications

media@legendbiotech.com

close

You are about to leave LegendBiotech.com

We use cookies to improve your experience on our website, measure performance, understand our audience, for advertising and support purposes. You can always change your preferences or opt out from our use of cookies.